Search results
Added:
1 year ago
Source:
Radcliffe Cardiology
AUTHOR: Sean DelaneyIn the landmark FAIR-HF2 randomized clinical trial (NCT03036462)1, intravenous (IV) ferric carboxymaltose did not significantly reduce heart failure (HF) hospitalizations or cardiovascular deaths in patients with heart failure and iron deficiency, despite improving patient-reported quality of life outcomes. Results were presented at ACC.252 and concurrently published in JAMA3…
View more
Added:
7 months ago
Source:
Radcliffe Cardiology
A prespecified secondary analysis of the DAN-RSV trial has found that a bivalent respiratory syncytial virus (RSV) vaccine is similarly effective against respiratory and cardiovascular outcomes in older adults, regardless of pre-existing atherosclerotic cardiovascular disease (ASCVD).¹The bivalent RSV prefusion F protein-based (RSVpreF) vaccine contains stabilised prefusion F glycoproteins from…
View more
Added:
9 months ago
Source:
Radcliffe Cardiology
A prespecified secondary analysis of the DANFLU-2 trial suggests that a high-dose inactivated influenza vaccine (HD-IIV) may offer greater protection against cardiovascular-related hospitalisations in older adults compared to a standard-dose vaccine (SD-IIV).¹˒² While the trial’s primary endpoint was not met, these exploratory findings point to a potential benefit in reducing the burden of…
View more
Added:
10 months ago
Source:
Radcliffe Cardiology
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and fatal disease characterised by the deposition of amyloid fibrils in the heart. A new analysis from the HELIOS-B trial has found that key echocardiographic measures are strong predictors of clinical outcomes and that the RNA interference (RNAi) therapeutic vutrisiran attenuates the decline in cardiac function in this patient…
View more
Added:
9 months ago
Source:
Radcliffe Cardiology
Results from the Phase III VICTOR trial, presented at the European Society of Cardiology (ESC) Congress 2025 and published in The Lancet, show that vericiguat did not meet its primary endpoint in patients with chronic, stable heart failure with reduced ejection fraction (HFrEF).¹˒²Vericiguat is an oral, once-daily stimulator of soluble guanylate cyclase (sGC), an enzyme in the nitric oxide…
View more
Added:
10 months ago
Source:
Radcliffe Cardiology
With global temperatures rising and heatwaves becoming more frequent and intense, the impact on public health is a growing concern. A new scientific statement from the European Society of Cardiology (ESC) and several of its constituent bodies highlights the significant risk that extreme heat poses to cardiovascular health, particularly for the elderly and individuals with pre-existing…
View more
Added:
11 months ago
Source:
Radcliffe CVRM
A secondary analysis of the SUMMIT trial has found that the benefits of tirzepatide on reducing the risk of cardiovascular death or worsening heart failure (HF) are consistent across all levels of obesity in patients with heart failure with preserved ejection fraction (HFpEF).¹ However, patients with a higher baseline body mass index (BMI) experienced greater improvements in exercise capacity and…
View more
Added:
4 months ago
Source:
Radcliffe Cardiology
Therapies for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), including transthyretin (TTR) stabilisers and silencers, have demonstrated a mortality benefit in randomised trials. However, the timing of this benefit has been a subject of debate. A new analysis of three major outcomes trials has evaluated this time course, revealing a consistent pattern across different treatments…
View more
Added:
1 year ago
Source:
THT
THT conference has released its four late-breaking trial sessions for 2025.The fourth annual Technology and Heart Failure Therapeutics conference is set to take place from the 11th to 13th February at Omni Boston Hotel at the Seaport in Boston. Access the full programme here.Late Breaking Clinical Science Session ITuesday 11th February, 09:30 – 10:45am ESTRobotic Surgical Technique for Performing…
View more
Added:
6 months ago
Source:
Radcliffe Cardiology
Cardiovascular magnetic resonance (CMR) with extracellular volume (ECV) mapping can effectively track changes in cardiac amyloid burden in transthyretin amyloid cardiomyopathy (ATTR-CM) and is independently associated with patient outcomes, according to a new prospective study.¹This single-centre prospective study included 189 patients with ATTR-CM. The cohort was divided into an untreated group …
View more